期刊文献+

反义核酸技术对人血管内皮细胞的改造作用

Reconstruction of Human Vascular Endothelial Cells with Antisense Nucleic Acid Technology
下载PDF
导出
摘要 为降低在血栓形成早期血管内皮细胞分泌的血管性血友病因子(vWF)对凝血级联反应的触发效应,利用反义核酸技术构建降低vWF表达量的血管内皮细胞.人工合成vWF部分反义核酸(pvWF)片段,构建重组的真核表达载体pcDNA3.1(+)/pvWF.测序正确后用脂质体介导的方法转染血管内皮细胞,硫酸新霉素加压筛选后扩大培养转基因细胞,RT-PCR法检测转基因细胞中vWF mRNA的表达水平.结果表明,构建的vWF反义核酸真核表达载体能有效抑制细胞中vWF mRNA的表达,为新型抗凝血材料的研究提供一种基因改造的内皮细胞. In early stages of the formation of thrombus, the von Willebrand factor(vWF) secreted by vascular endothelial cells-connects the platelet and the wounded site of inner wall of the vascellum and then originates the cascade reaction of blood coagulation. Vascular endothelial cells in which the expression of vWF is inhibited effectively can be constructed using antisense nucleic acid technology. An antisense nucleic acid fragment of vWF was artificially synthesized and then subcloned into eukaryotic expression plasmid pcDNA3.1(+)in the reverse direction. The plasmid pcDNA3.1(+)/pvWF was transfected by lipofectamine into vascular endothelial cells after being sequenced to confirm the correc- tion of gene. Transgenic cells were cultured in large scale after the selection using neomycin solution. Method of RT-PCR was used to investigate the vWF mRNA expression of transgenic cells. The result showed that the eukaryotic expression plasmid of vWF antisense nucleic acid could inhibit the vWF mRNA expression effectively. So a vascular endothelial cells model was set up that can express vWF antisense nucleic acid and the work provided a genetic reforming cell for the research of anticoagulated blood materials.
出处 《北京理工大学学报》 EI CAS CSCD 北大核心 2008年第2期181-184,共4页 Transactions of Beijing Institute of Technology
基金 国家“九七三”计划项目(2005CB623906)
关键词 反义核酸 血管性血友病因子 血管内皮细胞 antisense nucleic acid v Willebrand factor vascular endothelial cells
  • 相关文献

参考文献10

  • 1Biran R, Webb K, Noble M D, et al. Surfactant-immobilized fibronecin enhances bioactivity and regulates sensory neurite out growth [J ]. Journal of Biomedical Materials Research, 2001, 55:1-12.
  • 2S,adler J E. Biochemistry and genetics of yon Willebrand factor [J]. Annual Review of Biochemistry, 1998, 67: 395 - 424.
  • 3韩轩茂,任景芳,杨林花.vWF研究进展[J].血栓与止血学,2005,11(5):231-233. 被引量:7
  • 4张璞,肖传实.心血管疾病基因治疗[J].中国心血管病研究,2006,4(5):394-396. 被引量:5
  • 5陈援越,吕时铭.反义核酸技术的现状[J].国外医学(临床生物化学与检验学分册),2001,22(1):20-21. 被引量:5
  • 6Wickstrom E, Dekker M. Clinical trials of genetic therapy with antisense DNA and DNA vectors[J]. Trend in Pharmacological Sciences, 1999, 20 : 84 - 85.
  • 7李茂林,杨新林,朱鹤孙,王俐勇.反义核酸Ⅷ C真核表达载体的构建及其对转化血管内皮细胞的影响[J].自然科学进展,2002,12(12):1263-1267. 被引量:1
  • 8Murray J A. Antisense RNA and DNA[M]. New York: Wiley Liss Inc., 1992:1 - 49.
  • 9Sambrook J, Russell D W. Molecular cloning: a laboratory Mannual[M]. 3rd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 2001.
  • 10Kerr R, Stirling D, Rae M, et al. A novel method for quantitation of human yon Willebrand factor messenger RNA[J]. Thrombosis Research, 2002, 106 : 237 - 241.

二级参考文献43

  • 1[1]Shankaran H, Alexandridis P, Neelamegham S. Aspects of hydrodynamic shear regulating shear - induced platelet activation and selfassociation of von Willebrand factor in suspension[J]. Blood, 2003,101 (7) :2637 ~ 2645.
  • 2[2]Andrews RK, Berndt MC. Platelet physiology and thrombosis [J].Thromb Res, 2004,114(5 -6) :447 ~453.
  • 3[3]Nieswandt B, Watson SP. Platelet - collagen interaction: is GP Ⅵ the central receptor? [J] Blood, 2003,102(2) :449 ~461.
  • 4[4]Cruz MA, Chen J, Whiteloek JL, et al. The platelet glycoprotein Ib von Willebrand factor interaction activates the collagen receptor { alpha} 2 {beta} 1 to bind collagen: activation dependent conformational change of the { alpha } 2 - Ⅰ domain[J]. Blood, 2004, [Epub ahead of print]
  • 5[5]Sadler JE, Moake JL, Miyata T, et al. Recent advances in thrombotic thrombocytopenic purpura[J]. Hematology (Am Soc Hematol Educ Program), 2004, 407 ~4423.
  • 6[6]Bowen DJ, Collins PW. An amino acid polymorphism in von Willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13[J]. Blood, 2004,103(2) :941 ~947.
  • 7[7]Hilert L, Jorieux B, Proulle V, et al. Two mutation Q1053H and C1960R,located in the D3 domain of von Willebrand factor are responsible for decreased FⅧ -binding capacity[J]. Br J Haematol,2003,120(3) :941 ~947.
  • 8[8]Baronciani L, Cozzi G, Canciani, et al. Molecullar defects in types von Willebrand disease: updated results from 40 mutienthnic patient [J]. Blood Cells Mol Dis, 2003,30(1) :264 ~ 270.
  • 9[9]Makin AJ, Blann AD, Chung NA, et al. Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells. Relationship with von Willebrand factor and tissue factor[J]. Eur Heart J, 2004,25(5) :371 ~376.
  • 10[10]Nilsson TK, Bpence JD, Nilsson PM, et al. Quantitative measurement of carotid atherosclerosis in relation to levels of von Willebrand factor and fibrinolytic variables in plasma - a 2year followup study [J]. J Cardiovasc Risk, 2002,9(4) :215 ~221.

共引文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部